Key result
Senolytics and exercise reduce myocardial senescence by ~12 percentage points and improve diastolic function in mice.
Why the study?
Cellular senescence contributes to age-related cardiac dysfunction, but the long-term effects of senolytics and aerobic exercise, alone or combined, on myocardial senescence and function have not been evaluated.
Does chronic senolytic treatment and/or aerobic exercise reduce senescence and improve myocardial function in the aging heart?
RCT (n=64)
Blinded investigators for ultrasound analysis
Randomly allocated
No
Does chronic senolytic treatment and/or aerobic exercise reduce senescence and improve myocardial function in the aging heart?
Absolute Event Rate: 28.7% vs 40.7%
p-value: p=<0.05
Long-term aerobic exercise or senolytic therapy mitigates age-related cardiac dysfunction in mice by reducing the burden of cellular senescence in the myocardium.
May improve cardiac function in aged mice; leaves open translation to human aging therapies.
Aging is the predominant risk factor for cardiac dysfunction, driven primarily through a decline in cardiomyocyte and overall myocardial performance. Cellular senescence is becoming increasingly linked to its development, as senescent cardiomyocytes and interstitial cells accumulate with age and exhibit persistent DNA damage, mitochondrial dysfunction, and inflammation that collectively impair ventricular relaxation and contractility. Senolytics, which selectively eliminate senescent cells, effectively clear cardiac senescence and its burden, while aerobic exercise has shown promise as a non‐pharmacological intervention capable of modulating senescence. Despite this, neither approach has been evaluated as a long‐term preventive strategy or whether combining exercise with senolytics produces an additive effect. We hypothesized that when combined, chronic senolytics and aerobic exercise would produce a synergistic clearance of senescent myocardial cells leading to improved cardiac function. Male and female C57BL/6N mice (12‐months‐old) were randomly allocated to each group and received their intervention for 9‐months: naturally aged (VEH, n = 12), aerobic exercise (EX, n = 11), senolytics Dasatinib + Quercetin (D + Q) (SEN, n = 15) or both combined (SENEX, n = 16). Chronic D + Q, exercise, or both, significantly lowered the proportion of p16+, p21+, and γ‐H2AX+ cardiomyocytes and interstitial cells, while improving myocardial performance and diastolic function compared to naturally aged mice. At the whole‐heart level, protein expression of p16 and p21 increased with age, but was not altered alongside SASP by any intervention. Collectively, these findings demonstrate that long‐term exercise or senolytics limit senescence at the cellular level within the myocardium, and improve ventricular function, positioning exercise or senolytics as promising strategies to mitigate age‐related cardiac dysfunction.
No takes yet. Share an insight, caveat, or question.
Bevington et al. (2026) conducted an RCT in Aging-induced myocardial senescence and cardiac dysfunction (n=64). Senolytics (Dasatinib + Quercetin) and/or aerobic exercise vs. Vehicle (naturally aged) was evaluated on Proportion of p16+ cardiomyocytes (p=<0.05). Chronic administration of senolytics, aerobic exercise, or their combination for 9 months significantly reduced myocardial senescence markers (p16+ and p21+ cells) and improved diastolic function in aging mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: